Held by 3 specialist biotech funds
High Convergence# Signal Note: Rock Springs Capital Initiates MLYS Position Rock Springs' $15.5M entry into Mineralys suggests conviction in their lead candidate voxelotor (an anti-sickling agent for sickle cell disease), which has shown clinical promise in reducing hemolysis and vaso-occlusive crises.
AI analyst context — unlock full analysis
# Signal Note: RA Capital Initiates $265.8M Position in Mineralys RA Capital's $265.8M entry into Mineralys (7.3M shares) signals conviction in the company's clinical-stage mineral metabolism portfolio, likely driven by upcoming catalysts in hyperphosphatemia and/or secondary hyperparathyroidism. Kolchinsky's track record backing early-stage biotech with defined regulatory pathways suggests confidence in a near-term data readout or FDA milestone that could de-risk valuation. This is a substantial first position rather than exploratory stake, indicating material probability weighting of clinical/commercial success.
+ 1more — see how much conviction went in
See the Full Story